Literature DB >> 24008609

An internal medicine perspective review of risk factors for assessing and progression of primary open angle glaucoma.

A G Actis1, L Dall'Orto, R Penna, B Brogliatti, T Rolle.   

Abstract

Aim of this review was to resume risk factors for the assess and progression of primary open-angle glaucoma (POAG), particularly considering systemic risk factors that can be associated with glaucomatous damage. If intraocular pressure is the main risk factor, we must consider carefully familiarity, age, gender and possible associations with diabetes, hypertension, vascular autoregulation disorders, hypo- and hyperthyroidism, hypo- and hyperadrenalism, sleep apnea syndrome, corticosteroids therapies and other suspected factors cited in literature. Glaucoma's etiology remains unknown, its physiopathology is poorly understood and its diagnosis is often difficult. It is the leading cause of irreversible blindness worldwide and it is the real "silent thief of sight" because the loss of vision often occurs gradually over a long period of time, and symptoms only occur when the disease is quite advanced. Cost-effectiveness analyses for POAG screening are weighted by the degree of uncertainty that glaucoma screening can be effective and reliable achieved. Addressing patients to an ophthalmologic investigation on the basis of the identified risk factors is a fundamental preventing measure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24008609

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  10 in total

1.  Interaction between XRCC 1 gene polymorphisms and diabetes on susceptibility to primary open-angle glaucoma.

Authors:  Yanyan Wang; Chenguang Wang; Shounan Qi; Zaoxia Liu; Guanfang Su; Yajuan Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-11

2.  Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies.

Authors:  Ying-Xi Zhao; Xiang-Wu Chen
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

Review 3.  Association Between Diabetes, Diabetic Retinopathy, and Glaucoma.

Authors:  Yangjiani Li; William Mitchell; Tobias Elze; Nazlee Zebardast
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 5.430

4.  Long Term Results of Visual Field Progression Analysis in Open Angle Glaucoma Patients Under Treatment.

Authors:  Tolga Kocatürk; Sinan Bekmez; Merve Katrancı; Harun Çakmak; Volkan Dayanır
Journal:  Open Ophthalmol J       Date:  2015-06-26

5.  A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation.

Authors:  Jingfen Sun; Zhengshen Zhou
Journal:  Drug Des Devel Ther       Date:  2018-02-23       Impact factor: 4.162

6.  Histological Findings in the Trabecular Meshwork of a Patient with Atopic Glaucoma.

Authors:  Satoru Kase; Shiki Chin; Teruhiko Hamanaka; Yasuhiro Shinmei; Takeshi Ohguchi; Riki Kijima; Akira Matsuda; Susumu Ishida
Journal:  Open Ophthalmol J       Date:  2017-05-29

7.  Systemic diseases and their association with open-angle glaucoma in the population of Stockholm.

Authors:  Per Wändell; Axel C Carlsson; Gunnar Ljunggren
Journal:  Int Ophthalmol       Date:  2021-11-29       Impact factor: 2.029

8.  Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost.

Authors:  Mitsuhiro Imasawa; Joji Tanabe; Fumiko Kashiwagi; Kenji Kashiwagi
Journal:  Open Ophthalmol J       Date:  2016-03-07

9.  Risk Factors for Primary Open Angle Glaucoma (POAG) Progression: A Study Ruled in Torino.

Authors:  A G Actis; E Versino; B Brogliatti; T Rolle
Journal:  Open Ophthalmol J       Date:  2016-04-29

10.  Optic Disc and Macular Vessel Density Measured by Optical Coherence Tomography Angiography in Open-Angle and Angle-Closure Glaucoma.

Authors:  Tzu-Yu Hou; Tung-Mei Kuang; Yu-Chieh Ko; Yu-Fan Chang; Catherine Jui-Ling Liu; Mei-Ju Chen
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.